Get the Stockscreener App
2.39
9.06%
-0.205
Immix Biopharma Inc stock is traded at $2.39, with a volume of 279.18K.
It is down -9.06% in the last 24 hours and down -9.92% over the past month.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
See More
Previous Close:
$2.595
Open:
$2.62
24h Volume:
279.18K
Relative Volume:
1.02
Market Cap:
$66.21M
Revenue:
-
Net Income/Loss:
$-14.14M
P/E Ratio:
-2.5978
EPS:
-0.92
Net Cash Flow:
$-12.64M
1W Performance:
-13.24%
1M Performance:
-9.92%
6M Performance:
+17.41%
1Y Performance:
+15.69%
1-Day Range:
$2.35
$2.67
1-Week Range:
$2.35
$2.95
52-Week Range:
$1.26
$3.12
Immix Biopharma Inc Stock (IMMX) Company Profile
Name
Immix Biopharma Inc
Sector
Industry
Phone
(888) 958-1084
Address
11400 WEST OLYMPIC BLVD., LOS ANGELES
Compare IMMX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMMX
Immix Biopharma Inc
|
2.375 | 79.45M | 0 | -14.14M | -12.64M | -0.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
383.43 | 96.11B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.36 | 60.40B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
430.06 | 54.91B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
670.26 | 41.30B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
295.09 | 33.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Immix Biopharma Inc Stock (IMMX) Latest News
Visual analytics tools that track Immix Biopharma Inc. performanceFree Community Verified Stock Suggestions - Newser
ImmixBio plans to partner out CAR-T therapy for other diseases By Investing.com - Investing.com South Africa
Immix Biopharma Announces Other Serious Diseases Strategy - GlobeNewswire
Immix Biopharma's Game-Changing CAR-T Therapy Eyes Multiple Disease Markets Through Strategic Partnerships - Stock Titan
Pricing Power vs. Volume Pressure: What's Driving PepsiCo Now? - The Globe and Mail
Quantitative breakdown of Immix Biopharma Inc. recent moveFree AI Powered High Return Stock Calls - Newser
Can machine learning forecast Immix Biopharma Inc. recoveryFree Technical Stock Breakout Predictions - Newser
Market reaction to Immix Biopharma Inc.’s recent newsFree Smart Allocation Stock Pick Insights - Newser
Real time alert setup for Immix Biopharma Inc. performanceFree News Based Entry Opportunity Alerts - Newser
How moving averages guide Immix Biopharma Inc. tradingChart Driven Entry Timing for Swing Trades - Newser
Live market analysis of Immix Biopharma Inc.Free Fast Entry High Potential Stock Alerts - Newser
Can Traders Expect Breakout From Immix Biopharma Inc. This WeekSecure Capital Picks With Upside Potential Tracked - metal.it
Relative strength of Immix Biopharma Inc. in sector analysisFree Oversold Recovery Opportunity Stocks - Newser
Why Immix Biopharma Inc. stock attracts strong analyst attentionSmart Trend Analysis With Buy Point Cues - Newser
Will Immix Biopharma Inc. Stock Benefit from AI and Green Energy TrendsShort-Term AI-Based Stock Price Forecast - Newser
How many analysts rate Immix Biopharma Inc. as a “Buy”Turn market volatility into profit opportunities - Jammu Links News
Should I hold or sell Immix Biopharma Inc. stock in 2025Build wealth steadily with proven stock picks - Jammu Links News
What are analysts’ price targets for Immix Biopharma Inc. in the next 12 monthsCapitalize on fast-growing investment opportunities - Jammu Links News
What institutional investors are buying Immix Biopharma Inc. stockLightning-fast growth - Jammu Links News
What are the technical indicators suggesting about Immix Biopharma Inc.Achieve consistent profits with smart trading - Jammu Links News
When is Immix Biopharma Inc. stock expected to show significant growth - Jammu Links News
Immix Biopharma Inc. Stock Analysis and ForecastSuperior returns - Jammu Links News
How does Immix Biopharma Inc. generate profit in a changing economyAchieve breakthrough profits with smart strategies - Jammu Links News
Is it the right time to buy Immix Biopharma Inc. stockFree Stock Chart Pattern Guide - Jammu Links News
Real time social sentiment graph for Immix Biopharma Inc.Free Consistent Income Focused Trade List - newser.com
How does Immix Biopharma Inc. compare to its industry peersTurbocharged investment results - Jammu Links News
Is Immix Biopharma Inc. a good long term investmentDiscover market opportunities others miss - Jammu Links News
How volatile is Immix Biopharma Inc. stock compared to the marketCapitalize on emerging market sectors - Jammu Links News
What makes Immix Biopharma Inc. stock price move sharplyBuild a diversified portfolio for risk mitigation - Jammu Links News
Is Immix Biopharma Inc. Stock a Smart Buy in 2025 Investment Analysis InsideHigh Return Stock Focus With Safety Emphasized - beatles.ru
How strong is Immix Biopharma Inc. company’s balance sheetExpert Picks Entry Points For 2025 - Jammu Links News
Will Hims & Hers Fall Along With Novo Nordisk? - The Globe and Mail
Is Immix Biopharma Inc. a growth stock or a value stockSwing Trade Forecasts For Smart Trading - Jammu Links News
What are Immix Biopharma Inc. company’s key revenue driversPost Market Recommendation With High Returns - Jammu Links News
Using Ichimoku Cloud for Immix Biopharma Inc. technicalsFree Fast Return Equity Trade Forecast - Newser
Surge Energy Boosts 2025 Production Guidance and Cuts Capital Budget - The Globe and Mail
Volume Profile Shows Strong Base for Immix Biopharma Inc.Stock Market Entry Timing Signals Revealed - metal.it
Immix Biopharma Inc Stock (IMMX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Immix Biopharma Inc Stock (IMMX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Morris Gabriel S | CFO |
Jun 18 '25 |
Buy |
2.28 |
2,225 |
5,071 |
288,059 |
| Hsu Jason | Director |
Dec 23 '24 |
Buy |
2.19 |
40,000 |
87,680 |
893,000 |
| Hsu Jason | Director |
Dec 20 '24 |
Buy |
2.17 |
7,700 |
16,678 |
853,000 |
| Hsu Jason | Director |
Aug 21 '24 |
Buy |
2.23 |
15,000 |
33,390 |
837,200 |
| Hsu Jason | Director |
Aug 22 '24 |
Buy |
2.25 |
8,100 |
18,233 |
845,300 |
| Ng Carey | Director |
Aug 16 '24 |
Buy |
1.86 |
10,000 |
18,600 |
20,000 |
0.36%
1.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):